More than half a million genomics-based analyses have now been performed in routine healthcare in Sweden. This milestone represents a major breakthrough for precision diagnostics and highlights the results of nearly a decade of national collaboration to make advanced diagnostics accessible to patients across the entire country.
Sweden has reached an important milestone in precision diagnostics, according to an inventory of NGS-based analyses in Sweden conducted in 2025. Over the past nine years, the regions have together carried out more than 500,000 genomics-based analyses in routine healthcare, a clear result of shared initiatives, standards, and investments.
Through advanced genetic diagnostics, healthcare providers can today make more accurate diagnoses and take more precise treatment decisions. The fact that these technologies are now established throughout the country is a direct result of national coordination.
— Shared working methods and coordinated investments are absolutely crucial to ensure that advanced genomics benefits patients equitably and at scale across the entire country. No single region could have achieved this on its own, says Ann Ekberg Jansson, Head of Research and Development in Healthcare at the Västra Götaland Region.
In a short period of time, genomics-based diagnostics have evolved from a future vision into an integrated part of healthcare, particularly in cancer and rare diseases. Genomic Medicine Sweden (GMS) has played a central role in this development, together with the Clinical Genomics platform at SciLifeLab. Through national coordination, shared methods, standards, and infrastructure have made it possible to implement these technologies and make them accessible to patients throughout the country.
The number of analyses continues to increase in line with both medical needs and improved structures for collaboration.
For patients, this development means faster investigations, more reliable diagnoses, and better opportunities for precise, individualized treatment. For healthcare, it means higher quality, more efficient use of resources, and better conditions for knowledge development.
— Reaching more than 500,000 analyses within healthcare demonstrates that our collaborative efforts are delivering results and that the goal of one million analyses by 2030 is entirely realistic with continued effective national coordination. Through joint efforts, we can ensure that Swedish patients gain access to the next step in precision medicine, says Richard Rosenquist Brandell, Director of Genomic Medicine Sweden.